Suzlon wins 138 MW project from Cennergi in South Africa

If definitive agreements are reached, Suzlon will deliver the turbines under a full EPC agreement

Wind turbine manufacturer Suzlon Group has been selected as the preferred supplier by Cennergi for a 138 MW wind energy project currently under development in South Africa. No financial details of the deal were provided. Cennergi is an equal joint venture between South Africa’s Exxaro Resources (Exxaro) and the Tata Power Company, India`s largest private power utility.

Cennergi has chosen to use 66 of Suzlon’s S97-2.1 MW turbines for the project, located in the Eastern Cape Province of South Africa. If definitive agreements are reached, Suzlon will deliver the turbines under a full EPC (engineering, procurement and construction) agreement.

If it goes ahead, project construction is expected to commence towards 2013.
In the late afternoon, Suzlon Energy was trading at around Rs24.70 per share on the Bombay Stock Exchange, 1.79% down from the previous close.

User

Glenmark gets USFDA nod for oral contraceptive pills

The tablets are generic version of Janssen Pharmaceuticals Inc oral contraceptive Ortho Cyclen tablets

Drug firm Glenmark Pharmaceuticals said it has received final approval from the US health regulator for its generic contraceptive norgestimate and ethinyl estradiol tablets.

Glenmark Generics Inc, a subsidiary of Glenmark Generics has been granted final approval for their abbreviated new drug application (ANDA) by the US Food and Drug Administration (USFDA) for Norgestimate and Ethinyl Estradiol tablets in the strengths of 0.25 mg/0.035 mg, Glenmark Pharmaceuticals said in a statement.
The tablets are generic version of Janssen Pharmaceuticals Inc oral contraceptive Ortho Cyclen tablets.

Citing IMS Health data for the 12-month period ending December 2011, the company said norgestimate and ethinyl estradiol tablets of strength 0.25mg/0.035mg garnered total market sales of approximately $88 million.

The company currently has 79 generic products authorised for distribution in the US market and 39 ANDA’s pending approval with the USFDA, Glenmark said.
Today’s approval is Glenmark’s tenth female hormonal product authorised for distribution by the USFDA, it added.

In the late afternoon, Glenmark Pharmaceuticals was trading at around Rs308.05 per share on the Bombay Stock Exchange, 0.26% down from the previous close.

User

L&T Construction commissions India’s largest solar PV power plant

L &T Construction achieves 114MW of installations in a single year

L&T Construction has commissioned India’s largest solar photo voltaic based power plant (40 MWp) owned by Reliance Power Ltd at Dhursar Village, Jaisalmer district of Rajasthan. As the largest EPC player in solar power, L&T Construction executed the solar power plant from concept (including detailed design) to commissioning in 129 days. With the commissioning of this plant, L&T Construction has installed 114MW of utility scale solar PV power plants over the last fiscal–a benchmark in India’s solar EPC industry.

The solar PV power plant is equipped to supply more than 70 million units of clean and green energy to 75,000 households. The clean energy generated by the plant is expected to displace nearly 70,000 MT of CO2 annually.

The Solar PV power plant, which comprises more than 5,00,000 high output generating thin film technology based Solar PV modules and thirteen 3.5 MVA power transformers to generate 40MWp, is spread across 350 acres. The thin film Solar PV modules for the project were procured by Reliance Power; while L&T’s scope of work included complete design, engineering, procurement and construction of 40 MWp solar power plant, including construction of a 5km 33 kV double circuit transmission line.

In the early afternoon, Larsen & Toubro was trading at around Rs1,305 per share on the Bombay Stock Exchange,  3% down from the previous close.

User

COMMENTS

manish c parmar

5 years ago

I am intrested in civil construction & mechanicl work for solar project

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)